Ocular Therapeutix reported that Axpaxli (OTX‑TKI), a bioresorbable intravitreal hydrogel incorporating axitinib, met its primary superiority endpoint against a low‑dose Eylea comparator in the Sol‑1 Phase III trial for wet age‑related macular degeneration. Axpaxli maintained visual acuity in 74% of treated patients at the primary time point versus about 56% with the control. Investors reacted negatively, sending shares down after analysts noted the active control performed better than expected and questioned commercial differentiation in a market dominated by Regeneron and Roche. Company management highlighted the statistical superiority and the special protocol assessment‑aligned study design while acknowledging that real‑world positioning will require broader data and label discussions.